Navigation Links
Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial
Date:9/17/2007

MELBOURNE, Australia, Sept. 17 /PRNewswire-FirstCall/ -- Phosphagenics Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced that, following successful preclinical studies, it plans to undertake a Phase 1 transdermal oxycodone clinical trial aimed at providing chronic pain sufferers with a sustained-release pain management product.

Phosphagenics has submitted all necessary documents for approval of the trial, which is to be conducted at CMAX - an independent clinical research organization located at the Royal Adelaide Hospital. The trial, which will be in up to 30 healthy volunteers, will evaluate the tolerability and safety of the novel transdermal oxycodone. The trial will begin once approval has been received, which is expected within the next six weeks.

The Company is working towards becoming the first to provide chronic pain sufferers with a patch that will provide sustained-release of oxycodone into the bloodstream. Previous clinical trials have demonstrated that Phosphagenics' patented technologies can effectively deliver opiates through the skin without causing any disruption or irritation.

Harry Rosen, Phosphagenics' President and CEO, said: "We have prioritized oxycodone over morphine in our pain management pipeline as we are in commercial discussions with several companies.

"These companies' commercial interests are focused on the license of a transdermal pain product containing oxycodone."

Dr. Esra Ogru, Executive Vice President of Research and Development at Phosphagenics, said: "Our objective is to address a large unmet need by using our technology to deliver oxycodone in a sustained-release formulation to treat pain beyond a 24 hour period."

Oxycodone, currently administered in tablet or intravenous form, in an eight to 12 hour formulation, is more potent than morphine with fewer adverse effects and its worldwide sales exceed $1 billion annually.

About Phosphagenics Limited

Phosphagenics is a
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
2. Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
3. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
4. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... Wash. , Oct. 20, 2014 CTI ... that it will report its third quarter 2014 financial ... of the U.S. financial markets. Following the announcement, members ... call to discuss the results and provide a general ... Access to the event can be obtained as follows: ...
(Date:10/17/2014)... , Oct. 17, 2014 With ... Medical Affairs function has come across several challenges ... efficiently and managing globalization.  The ... LLC is dedicated to providing benchmarking and best ... Affairs Consortium is a service composed of three ...
(Date:10/17/2014)... 2014 UBM Medica US announces that ... and information resource for neurologists and other healthcare providers, features ... disease , with discussions of the latest developments in approaches ... have Parkinson disease , more than the total of those ... disease. Diagnosis can be difficult because there are no ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Early Key Findings from the Medical Affairs Consortium Research 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3
... , Strategic collaboration with Ipsen for marketing rights ... and the US , Photocure to commercialise the ... ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic ... a new commercial strategy for Hexvix, its flagship product  to ...
... FRANCISCO, Calif., Sept. 26, 2011 diaDexus, Inc. (OTC ... focused on the development and commercialization of patent-protected in ... today announced the Board of Directors, appointment of a ... a new chief business officer, R. Michael Richey. Dr. ...
Cached Medicine Technology:Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 2Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 3Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 4Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 5Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 6Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 7Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 8diaDexus Appoints New CEO Brian E. Ward, Ph.D. and New CBO Michael Richey 2diaDexus Appoints New CEO Brian E. Ward, Ph.D. and New CBO Michael Richey 3diaDexus Appoints New CEO Brian E. Ward, Ph.D. and New CBO Michael Richey 4diaDexus Appoints New CEO Brian E. Ward, Ph.D. and New CBO Michael Richey 5
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 Allegheny ... minimally-invasive procedure that enables physicians to repair a damaged ... The MitraClip system, developed by Abbott ... (MR), a progressive and life-threatening condition in which the ... blood to flow backward from the heart’s left ventricle ...
(Date:10/20/2014)... IN (PRWEB) October 20, 2014 ... Start, a secure cloud solution that enables healthcare ... of the ultimate healthcare-specific customer relationship management (“CRM”) ... meet the unique needs of the healthcare industry, ... experience for providers and patients by combining healthcare ...
(Date:10/20/2014)... San Diego, CA (PRWEB) October 20, 2014 ... regarding all the latest information from the FDA on ... consumers on October 10 not to purchase or use Sit ... Phenolphthalein. Sit and Slim II is promoted as weight loss ... , Sibutramine, removed from the market in 2010 for safety ...
(Date:10/20/2014)... Columbus, OH (PRWEB) October 20, 2014 National ... Ohio Chapter of the American Academy of Pediatrics (Ohio AAP, ... Administration (NHTSA) in encouraging parents of teen drivers to talk ... hit the road. , Motor vehicle crashes are the leading ... 2,055 teen drivers involved in fatal crashes, and 859 (42%) ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Houston plastic ... present the key elements of his innovative True ... to plastic surgery residents and faculty at The ... where he, too, was once a medical student. Patronella, ... largest private cosmetic plastic surgery practices in Texas, ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... scientists at Johns Hopkins have linked a gene that allows ... houses insects and worms to the severe congestion and polyp ... sinus experts has found that the gene for the enzyme, ... active in people with severe sinus inflammation that persists even ...
... resistant bacterial infections scientists have developed a new ... spread infection//. With this approach bacteria has been rendered ... the battle against bacteria in the light of several ... drug resistance. ,Tests have shown that these ...
... and Drug Administration has charged the American Red Cross yet ... to the stipulation of safe blood collection techniques.// The Red ... the nation's requirement of blood, has been under the vigilance ... make the blood safe by enhancing the quality control system., ...
... girl athletes are as much as eight times more ... than their male counterparts, according to a recent study ... Columbia University Medical Center. Published in the American Journal ... why the knee injury disproportionately affects mature girls. The ...
... the disturbance in balance of the electrical signals being sent ... be careful when driving since seizures can be triggered off ... says that epilepsy can be triggered by 'conditions that affect ... disease can be inherited.' ,In most people anti-convulsant medications ...
... was $8.9 billion against the need of $14.9 billion. ... to maximize the treatment and prevention strategies for their ... the issue through cost benefit and cost effectiveness analysis. ... September 13 to Friday, September 15, 2006 in Boston, ...
Cached Medicine News:Health News:Immune Response Linked to “Ghost” Parasites and Severely Congested Sinus 2Health News:Immune Response Linked to “Ghost” Parasites and Severely Congested Sinus 3Health News:Immune Response Linked to “Ghost” Parasites and Severely Congested Sinus 4Health News:Latest Weapon in Battle against Drug-Resistant Bacteria 2Health News:Adolescent Girl Athletes More Likely to Injure Knees Than Boys 2Health News:International Conference on The Costs And Benefits of HIV/AIDS Interventions in Developing Countries to be hosted by Harvard 2
... lumen tube made of silicone rubber with a ... the characteristics of silicone rubber, Silbronco is soft ... Furthermore, the tube will not soften like PVC ... surgery., ,Silbronco is also especially useful when ...
... endobronchial blockade of the ... for procedures which require ... consists of an endobronchial ... Arndt Multiport Airway Adapter. ...
... The Mini-Trach® II kit includes a ... 15 mm ISO connector, and a 10fr ... provides the necessary components needed to perform ... kit, a small bore cannula (4.0 mm ...
... Steel. Non-Sterile Howland lock handle - Chrome-plated ... high quality standard laryngoscope handles that are ... ISO 7673 standards. The designs of these ... years of use the world over to ...
Medicine Products: